News

OKLAHOMA CITY, OKLAHOMA, March 1, 2010 – Cytovance® Biologics LLC announced today that it is launching dedicated business development activities in International markets for biologic contract manufacturing of therapeutic proteins and monoclonal antibodies.  In a newly created position, Molly S. McGlaughlin MeD, has been appointed as Vice President of Sales & Business Development – International, and will be spearheading this critical strategic growth initiative.  Molly joined Cytovance in 2008 as Vice President of Sales & Business Development and rapidly established Cytovance as a premier biologics contract manufacturing organization in providing a comprehensive menu of biopharmaceutical development and cGMP manufacturing services.  Molly and her team were responsible for the robust revenue growth through securing custom-designed development and manufacturing agreements with numerous clients. 

William Dull has been appointed as Vice President of Sales & Business Development – North America, and will be responsible for Cytovance’s business development activities in North America, including the marketing and sales.  Mr. Dull comes to Cytovance with over 24 years of successful experience in the biotech and pharmaceutical industry in particular U.S. and worldwide marketing and sales, medical affairs and strategic and commercial planning.  Mr. Dull has held senior positions of increasing responsibility at ARCA biopharma, Scios, Transkaryotic Therapies (TKT) now Shire Human Genetic Therapies (HGT), Bio-Technology General now Savient Pharmaceuticals and Genentech.    

These tactical changes create opportunities to enhance the global business as Cytovance continues expanding its world class manufacturing operations.  Once complete, the custom-designed facility will house an additional 1,000L and two 5,000L scale manufacturing process trains for mammalian production,  a 1,000L microbial facility as well as additional laboratory space.  This state-of-the-art Bio-Analytical Development laboratory is being led by Dr. Jeffrey Su.  Dr. Su has an extensive background in biologic process and analytic development and production of biotherapeutics.  This expansion is a direct result of client demand for clinical and commercial scale protein-based biopharmaceutical products. 

“Cytovance is strategically positioning itself to be a global partner to support the growing developmental and capacity needs of our current and future clients.  We recognize the importance of adding to our current manufacturing facility and broadening our business reach by focusing on promising biotechnology companies in Europe and Asia.  We offer a comprehensive and collaborative approach to manufacturing biologics that adds significant value by partnering with biopharmaceutical companies to advance their recombinant protein, antibody and cell-based therapeutic products rapidly and cost-effectively from the laboratory, through clinical development and to commercial launch in all geographical markets,” said Darren Head, President & Chief Executive Officer of Cytovance.

“Molly’s successful track record will be a valuable asset as we promote our services in emerging markets and William’s cross-functional business background adds great depth to our leadership team.  The complete Cytovance team recognizes our facility and personnel expansion as an integral element to our business model and a testament to our commitment to meet the science and outsourcing manufacturing requirements of our global customers.”

About Cytovance Biologics
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and monoclonal antibodies from mammalian and microbial cell culture. An experienced management team formed the company to address the biotechnology industry's increasing needs for full-service manufacturing capacity at the clinical and early commercial scale. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City, Oklahoma facilities.  The company’s approach couples considerable client-side experience with the necessary technical and operational expertise to deliver effective processes, products and the supporting know-how that meet international regulatory standards and facilitate efficient completion of clinical development. For more information on Cytovance, visit www.cytovance.com.

Media Contact:
Fawn Meeks
fmeeks@cytovance.com